Systemic Administration of NMDA and AMPA Receptor Antagonists Reverses the Neurochemical Changes Induced by Nigrostriatal Denervation in Basal Ganglia-Reference-Cited by-同舟云学术

Systemic Administration of NMDA and AMPA Receptor Antagonists Reverses the Neurochemical Changes Induced by Nigrostriatal Denervation in Basal Ganglia

Published:2002-01-18 Issue:1 Volume:73 Page:344-352
ISSN:0022-3042
Container-title:Journal of Neurochemistry
language:en
Short-container-title:

Author:

Vila Miquel,Marin Concepció,Ruberg Merle,Jimenez Anna,Raisman-Vozari Rita,Agid Yves,Tolosa Eduardo,Hirsch Etienne C.

Publisher

Wiley

Subject

Cellular and Molecular Neuroscience,Biochemistry

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1046/j.1471-4159.1999.0730344.x/fullpdf

Reference60 articles.

1. Excitatory amino acid binding sites in the basal ganglia of the rat: a quantitative autoradiographic study.;Albin;Neuroscience,1992

2. Synaptic plasticity in the striatum of patients with Parkinson’s disease.;Anglade;Neurodegeneration,1996

3. Lesions of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate.;Aziz;Mov. Disord.,1991

4. Reversal of rigidity and improvement in motor performance by subthalamic high-frequency stimulation in MPTP-treated monkeys.;Benazzouz;Eur. J. Neurosci.,1993

5. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus.;Bergman;Science,1990

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. NMDA receptor antagonism potentiates the l-DOPA-induced extracellular dopamine release in the subthalamic nucleus of hemi-parkinson rats;Neuropharmacology;2014-10

2. Allosteric modulation of the group III mGlu4 receptor provides functional neuroprotection in the 6-hydroxydopamine rat model of Parkinson's disease;British Journal of Pharmacology;2012-07-24

3. Riluzole neuroprotection in a parkinson's disease model involves suppression of reactive astrocytosis but not GLT-1 regulation;BMC Neuroscience;2012-04-05

4. Therapeutic potential of targeting group III metabotropic glutamate receptors in the treatment of Parkinson's disease;British Journal of Pharmacology;2010-05-19

5. Symptomatic and neuroprotective effects following activation of nigral group III metabotropic glutamate receptors in rodent models of Parkinson's disease;British Journal of Pharmacology;2010-04-26